Patients
fluoropyrimidine‐based
ONCOLOGY
From January 2017 to December 2017, 7 patients were treated with abemaciclib plus galunisertib (safety lead‐in), and 99 patients were randomized to receive abemaciclib (Arm A: Summary of patient disposition.Demographics and baseline characteristics (safety lead‐in and ITT population).Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; Baseline characteristics are missing for 1 patient.Some categories do not add up to 100% due to rounding.6 patients (1 in abemaciclib plus galunisertib, 2 in abemaciclib monotherapy arm, and 3 in SOC arm) had missing stage at diagnosis.Categories do not add up to 100% as nearly half of the patients previously received both gemcitabine‐ and fluoropyrimidine‐based therapies.